Completed PHASE3 INTERVENTIONAL 4-arm NCT01323972

Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children

Consistency of Immunogenicity and Non Inferiority of Three Production Lots of GSK Biologicals' Candidate Malaria Vaccine in Children

Sponsor: GlaxoSmithKline

Conditions Malaria

Interventions GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)

Updated 7 times since 2017 Last updated: Jun 22, 2018 Started: May 16, 2011 Primary completion: Nov 22, 2011 Completion: May 4, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Malaria and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Sep 2018 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Sep 2017 [monthly]

Completed PHASE3

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
The PATH Malaria Vaccine Initiative (MVI)

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Enugu, Nigeria
• Jos, Nigeria